Diagnosis and differential assessment of pulmonary arterial hypertension

Robyn J. Barst, Michael McGoon, Adam Torbicki, Olivier Sitbon, Michael Joseph Krowka, Horst Olschewski, Sean Gaine

Research output: Contribution to journalArticle

748 Citations (Scopus)

Abstract

Pulmonary arterial hypertension (PAH) is diagnosed by various investigations that are essential for making the diagnosis, and by additional tests to clarify the category of pulmonary hypertension (PH). A diagnostic algorithm can guide the evaluation of PH, but like all guidelines the algorithm can be modified according to specific clinical circumstances. Most patients are diagnosed as the result of an evaluation of symptoms, whereas others are diagnosed during screening of asymptomatic populations at risk. Right heart catheterization (RHC) must be performed in patients with suspected PH to establish the diagnosis and document pulmonary hemodynamics. Before initiation of medical therapy, assessment of acute vasoreactivity (during catheterization) is necessary to determine the appropriate therapy for an individual patient. An acute response is generally defined as a decrease in mean pulmonary arterial pressure of at least 10 mm Hg with the mean pulmonary arterial pressure decreasing to 40 mm Hg or below, accompanied by a normal or high cardiac output. After PAH is diagnosed, disease severity should be assessed in order to accurately determine risk:benefit profiles for various therapeutic options. Useful tools to predict outcome include functional class, exercise capacity, pulmonary hemodynamics, acute vasoreactivity, right ventricular function, as well as brain natriuretic peptide, endothelin-1, uric acid, and troponin levels. Repeating these tests serially on treatment is useful for monitoring the response to a given therapy. Close follow-up at a center specializing in management of PH is recommended, with careful periodic reassessment and adjustment of therapy.

Original languageEnglish (US)
JournalJournal of the American College of Cardiology
Volume43
Issue number12 SUPPL.
DOIs
StatePublished - Jun 16 2004

Fingerprint

Pulmonary Hypertension
Differential Diagnosis
Lung
Arterial Pressure
Therapeutics
Hemodynamics
High Cardiac Output
Right Ventricular Function
Troponin
Symptom Assessment
Brain Natriuretic Peptide
Endothelin-1
Cardiac Catheterization
Uric Acid
Catheterization
Guidelines
Exercise

Keywords

  • BMI
  • body mass index
  • cardiac index
  • chronic thromboembolic pulmonary hypertension
  • CI
  • CTEPH
  • ECG
  • electrocardiogram
  • idiopathic pulmonary arterial hypertension
  • IPAH
  • PA
  • PAH
  • PASP
  • pulmonary arterial hypertension
  • pulmonary artery

ASJC Scopus subject areas

  • Nursing(all)
  • Cardiology and Cardiovascular Medicine

Cite this

Diagnosis and differential assessment of pulmonary arterial hypertension. / Barst, Robyn J.; McGoon, Michael; Torbicki, Adam; Sitbon, Olivier; Krowka, Michael Joseph; Olschewski, Horst; Gaine, Sean.

In: Journal of the American College of Cardiology, Vol. 43, No. 12 SUPPL., 16.06.2004.

Research output: Contribution to journalArticle

Barst, Robyn J. ; McGoon, Michael ; Torbicki, Adam ; Sitbon, Olivier ; Krowka, Michael Joseph ; Olschewski, Horst ; Gaine, Sean. / Diagnosis and differential assessment of pulmonary arterial hypertension. In: Journal of the American College of Cardiology. 2004 ; Vol. 43, No. 12 SUPPL.
@article{3e5bd314632b48a8abb14c58f9af3d2f,
title = "Diagnosis and differential assessment of pulmonary arterial hypertension",
abstract = "Pulmonary arterial hypertension (PAH) is diagnosed by various investigations that are essential for making the diagnosis, and by additional tests to clarify the category of pulmonary hypertension (PH). A diagnostic algorithm can guide the evaluation of PH, but like all guidelines the algorithm can be modified according to specific clinical circumstances. Most patients are diagnosed as the result of an evaluation of symptoms, whereas others are diagnosed during screening of asymptomatic populations at risk. Right heart catheterization (RHC) must be performed in patients with suspected PH to establish the diagnosis and document pulmonary hemodynamics. Before initiation of medical therapy, assessment of acute vasoreactivity (during catheterization) is necessary to determine the appropriate therapy for an individual patient. An acute response is generally defined as a decrease in mean pulmonary arterial pressure of at least 10 mm Hg with the mean pulmonary arterial pressure decreasing to 40 mm Hg or below, accompanied by a normal or high cardiac output. After PAH is diagnosed, disease severity should be assessed in order to accurately determine risk:benefit profiles for various therapeutic options. Useful tools to predict outcome include functional class, exercise capacity, pulmonary hemodynamics, acute vasoreactivity, right ventricular function, as well as brain natriuretic peptide, endothelin-1, uric acid, and troponin levels. Repeating these tests serially on treatment is useful for monitoring the response to a given therapy. Close follow-up at a center specializing in management of PH is recommended, with careful periodic reassessment and adjustment of therapy.",
keywords = "BMI, body mass index, cardiac index, chronic thromboembolic pulmonary hypertension, CI, CTEPH, ECG, electrocardiogram, idiopathic pulmonary arterial hypertension, IPAH, PA, PAH, PASP, pulmonary arterial hypertension, pulmonary artery",
author = "Barst, {Robyn J.} and Michael McGoon and Adam Torbicki and Olivier Sitbon and Krowka, {Michael Joseph} and Horst Olschewski and Sean Gaine",
year = "2004",
month = "6",
day = "16",
doi = "10.1016/j.jacc.2004.02.032",
language = "English (US)",
volume = "43",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "12 SUPPL.",

}

TY - JOUR

T1 - Diagnosis and differential assessment of pulmonary arterial hypertension

AU - Barst, Robyn J.

AU - McGoon, Michael

AU - Torbicki, Adam

AU - Sitbon, Olivier

AU - Krowka, Michael Joseph

AU - Olschewski, Horst

AU - Gaine, Sean

PY - 2004/6/16

Y1 - 2004/6/16

N2 - Pulmonary arterial hypertension (PAH) is diagnosed by various investigations that are essential for making the diagnosis, and by additional tests to clarify the category of pulmonary hypertension (PH). A diagnostic algorithm can guide the evaluation of PH, but like all guidelines the algorithm can be modified according to specific clinical circumstances. Most patients are diagnosed as the result of an evaluation of symptoms, whereas others are diagnosed during screening of asymptomatic populations at risk. Right heart catheterization (RHC) must be performed in patients with suspected PH to establish the diagnosis and document pulmonary hemodynamics. Before initiation of medical therapy, assessment of acute vasoreactivity (during catheterization) is necessary to determine the appropriate therapy for an individual patient. An acute response is generally defined as a decrease in mean pulmonary arterial pressure of at least 10 mm Hg with the mean pulmonary arterial pressure decreasing to 40 mm Hg or below, accompanied by a normal or high cardiac output. After PAH is diagnosed, disease severity should be assessed in order to accurately determine risk:benefit profiles for various therapeutic options. Useful tools to predict outcome include functional class, exercise capacity, pulmonary hemodynamics, acute vasoreactivity, right ventricular function, as well as brain natriuretic peptide, endothelin-1, uric acid, and troponin levels. Repeating these tests serially on treatment is useful for monitoring the response to a given therapy. Close follow-up at a center specializing in management of PH is recommended, with careful periodic reassessment and adjustment of therapy.

AB - Pulmonary arterial hypertension (PAH) is diagnosed by various investigations that are essential for making the diagnosis, and by additional tests to clarify the category of pulmonary hypertension (PH). A diagnostic algorithm can guide the evaluation of PH, but like all guidelines the algorithm can be modified according to specific clinical circumstances. Most patients are diagnosed as the result of an evaluation of symptoms, whereas others are diagnosed during screening of asymptomatic populations at risk. Right heart catheterization (RHC) must be performed in patients with suspected PH to establish the diagnosis and document pulmonary hemodynamics. Before initiation of medical therapy, assessment of acute vasoreactivity (during catheterization) is necessary to determine the appropriate therapy for an individual patient. An acute response is generally defined as a decrease in mean pulmonary arterial pressure of at least 10 mm Hg with the mean pulmonary arterial pressure decreasing to 40 mm Hg or below, accompanied by a normal or high cardiac output. After PAH is diagnosed, disease severity should be assessed in order to accurately determine risk:benefit profiles for various therapeutic options. Useful tools to predict outcome include functional class, exercise capacity, pulmonary hemodynamics, acute vasoreactivity, right ventricular function, as well as brain natriuretic peptide, endothelin-1, uric acid, and troponin levels. Repeating these tests serially on treatment is useful for monitoring the response to a given therapy. Close follow-up at a center specializing in management of PH is recommended, with careful periodic reassessment and adjustment of therapy.

KW - BMI

KW - body mass index

KW - cardiac index

KW - chronic thromboembolic pulmonary hypertension

KW - CI

KW - CTEPH

KW - ECG

KW - electrocardiogram

KW - idiopathic pulmonary arterial hypertension

KW - IPAH

KW - PA

KW - PAH

KW - PASP

KW - pulmonary arterial hypertension

KW - pulmonary artery

UR - http://www.scopus.com/inward/record.url?scp=2942603006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942603006&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2004.02.032

DO - 10.1016/j.jacc.2004.02.032

M3 - Article

C2 - 15194177

AN - SCOPUS:2942603006

VL - 43

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 12 SUPPL.

ER -